#ESMO17 roundup: Idera shares spike on early TLR9 combo data; Erytech touts pancreatic cancer PhIIb data
MADRID — Shares of Idera $IDRA shot up 20% in pre-market trading on Monday as investors caught up with an encouraging look at early-stage data for its TLR9 drug IMO-2125 with Bristol-Myers’ Yervoy. Researchers tracked a 44% response rate — 4 of 9 patients who had failed Keytruda or Opdivo. There was one complete response in the group, who faced poor odds in fighting their tumors.
Erytech red blood cell therapy promising in PhIIb pancreatic cancer study
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
